Tocqueville Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-667
Closed -$2K 772
2018
Q4
$2K Hold
667
﹤0.01% 739
2018
Q3
$5K Hold
667
﹤0.01% 811
2018
Q2
$5K Hold
667
﹤0.01% 820
2018
Q1
$23K Hold
667
﹤0.01% 819
2017
Q4
$28K Hold
667
﹤0.01% 790
2017
Q3
$29K Hold
667
﹤0.01% 801
2017
Q2
$25K Hold
667
﹤0.01% 780
2017
Q1
$36K Hold
667
﹤0.01% 791
2016
Q4
$35K Hold
667
﹤0.01% 794
2016
Q3
$40K Hold
667
﹤0.01% 814
2016
Q2
$44K Hold
667
﹤0.01% 826
2016
Q1
$38K Sell
667
-4,226
-86% -$475K ﹤0.01% 847
2015
Q4
$1.15M Buy
4,893
+1,733
+55% +$378K 0.02% 514
2015
Q3
$500K Sell
3,160
-73
-2% -$20.7K 0.01% 696
2015
Q2
$1.22M Buy
3,233
+66
+2% +$26.2K 0.01% 534
2015
Q1
$1.32M Buy
3,167
+667
+27% +$239K 0.02% 540
2014
Q4
$684K Buy
2,500
+580
+30% +$144K 0.01% 642
2014
Q3
$373K Sell
1,920
-323
-14% -$70.4K ﹤0.01% 685
2014
Q2
$549K Sell
2,243
-1,080
-33% -$244K 0.01% 702
2014
Q1
$881K Buy
3,323
+200
+6% +$76.6K 0.01% 468
2013
Q4
$1.13M Buy
3,123
+1,430
+84% +$551K 0.02% 432
2013
Q3
$900K Buy
1,693
+320
+23% +$110K 0.01% 528
2013
Q2
$322K Buy
+1,373
New +$270K ﹤0.01% 758

Other funds holding CLDX

Tocqueville Asset Management's CLDX Position: Q1 2019 in Review

Tocqueville Asset Management sold out of Celldex Therapeutics (CLDX) in Q1 2019, closing a stake of 667 shares — an estimated $2K sold.

Tocqueville Asset Management first reported a position in CLDX in Q2 2013 and held it in 23 quarters. The position peaked at $1.32M in Q1 2015. 53 funds tracked by Wall St. Rank hold CLDX as of Q1 2019.

  • Tocqueville Asset Management reported no remaining Celldex Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Tocqueville Asset Management sold 667 Celldex Therapeutics shares in Q1 2019, an estimated $2K.
  • Tocqueville Asset Management first reported a position in Celldex Therapeutics in Q2 2013 and held it in 23 quarters.
  • Tocqueville Asset Management's Celldex Therapeutics position peaked at $1.32M in Q1 2015.
  • 53 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2019.

Based on Tocqueville Asset Management's 13F filing for Q1 2019, filed 30 Apr 2019.